此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Automated Reporting System for Biliopancreatic Endoscopic Ultrasound

2026年11月9日 更新者:Qilu Hospital of Shandong University

Development and Prospective Multicenter Validation of an Automated Reporting System for Biliopancreatic Endoscopic Ultrasound

This study aims to develop and prospectively validate an automated reporting system to generate structured preliminary biliopancreatic EUS reports using information collected before and during EUS examinations. System development will be completed before prospective validation, and patients included in system development will be separate from those enrolled in prospective validation.

The prospective multicenter validation will enroll 420 adults undergoing EUS for suspected or confirmed biliopancreatic disease. Each patient will contribute only the first eligible EUS examination. The primary endpoint is the difference in clinical acceptance rates between system-generated preliminary reports and independently prepared manual preliminary reports. Non-inferiority will be assessed using a predefined margin.

A nested endosonographer-reporting substudy will also compare completion time and quality between final reports prepared by endosonographers with and without assistance of a system-generated preliminary report. The study will assess the ability of automated reporting to support accurate and efficient EUS reporting while routine clinical care remains unchanged.

研究概览

详细说明

This study aims to develop and validate an automated reporting system which will generate structured preliminary reports based on preprocedural clinical data, the endosonographer's speech during EUS, EUS videos, and EUS procedural records. System development will be completed before prospective validation, using a dataset separated from the prospective validation cohort.

The prospective multicenter validation will enroll 420 adults undergoing EUS for suspected or confirmed biliopancreatic diseases. Each patient will contribute only the first eligible EUS examination as the index EUS examination. For each index examination, the automated reporting system will generate a system-generated preliminary report, while the examining endosonographer will independently generate the manual preliminary report without AI assistance. Additionally, speech-only preliminary reports and video-only preliminary reports will be generated to explore the contribution of different data inputs.

Each report will be independently assessed by two EUS experts blinded to the report source. Disagreements between the two assessors will be adjudicated by a third expert. Significant clinical corrections are defined as corrections to errors or omissions that could affect lesion localization, diagnosis, or subsequent clinical management; word and format changes alone do not qualify as significant clinical corrections. Clinical acceptance rate is defined as the proportion of all reports generated for enrolled patients that were accepted without significant clinical corrections. The primary endpoint is the difference in clinical acceptance rates between the system-generated preliminary report and the manual preliminary report of the same patient.

Additionally, a predefined nested endosonographer-reporting substudy will use the same cases to compare completion time and quality between final reports prepared by endosonographers with and without assistance of a system-generated preliminary report. Reporting tasks will be randomly assigned to endosonographers. This substudy will evaluate whether the automated reporting system can improve reporting efficiency while maintaining final report quality.

研究类型

观察性的

注册 (估计的)

420

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Shandong
      • Jinan、Shandong、中国、250012
        • Qilu Hospital of Shandong University
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

不超过 18年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Adults undergoing EUS for suspected or confirmed biliopancreatic disease at participating hospitals.

描述

Inclusion Criteria:

  1. Patients aged ≥ 18years;
  2. Patients undergoing EUS for suspected or confirmed biliopancreatic disease;
  3. Patients who voluntarily sign the informed consent.

Exclusion Criteria:

  1. Patients who are unable to complete standard scanning due to gastrointestinal obstruction or other reasons;
  2. Patients who underwent surgical treatment or anatomical alterations of the pancreas due to lesions in other thoracic and/or abdominal organs, as well as patients with congenital anatomical abnormalities;
  3. Patients undergoing EUS primarily for therapeutic purpose such as drainage.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Adults undergoing biliopancreatic endoscopic ultrasound

Adults undergoing EUS for suspected or confirmed biliopancreatic diseases will participate in this study. Each patient provides only the first eligible EUS examination for a prospective validation of the automated reporting system.

The system that integrates preprocedural clinical data, the endosonographer's speech during EUS, EUS videos, and EUS procedural records to generate a system-generated preliminary report. The system-generated preliminary report is generated for research validation after the routine EUS examination and is compared with the endosonographer's independent manual preliminary report. The system does not determine the patient's clinical care.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Difference in clinical acceptance rates between system-generated and manual preliminary reports
大体时间:Preliminary reports from the index EUS examination; assessment within 60 days after EUS.

The within-patient paired difference in clinical acceptance rates, calculated as the rate for system-generated preliminary reports minus that for independently written manual preliminary reports. A report is accepted if it requires no significant clinical corrections-corrections to errors or omissions that could affect lesion localization, diagnosis or clinical management. Failed or blank system-generated reports are classified as not accepted. Non-inferiority is established if the lower limit of the two-sided 95% confidence interval is greater than -5 percentage points.

Preliminary reports from the index EUS examination; assessment within 60 days after EUS.

次要结果测量

结果测量
措施说明
大体时间
Completeness of the system-generated preliminary reports
大体时间:Index EUS examination; report assessment within 60 days.

In the prospective paired validation, completeness is the proportion of applicable, reference-confirmed items correctly documented in each system-generated preliminary report. Items cover actual examination extent, organ findings, lesion descriptions, and sampling records.

Index EUS examination; report assessment within 60 days.
Number of significant clinical report corrections
大体时间:Index EUS examination; report assessment within 60 days.

In the prospective paired validation, the number of significant clinical corrections required per system-generated preliminary report will be assessed. Reductions and additions relative to the independent manual preliminary report will also be reported.

Index EUS examination; report assessment within 60 days.
Reporting time of the system-generated preliminary report
大体时间:During the first automated report-generation task for the index EUS examination, within 30 days after EUS.

In the prospective paired validation, time is measured from submission of all required inputs-including preprocedural clinical data, the endosonographer's speech, EUS videos, and EUS procedure records-to availability of the first system-generated preliminary report. Failed generation will be reported separately.

During the first automated report-generation task for the index EUS examination, within 30 days after EUS.
Reporting time of the manual preliminary report
大体时间:During the routine reporting session immediately after the index EUS examination, up to 60 days

Description: In the prospective paired validation, time is measured from the endosonographer beginning routine report preparation to submission of the independent manual preliminary report, without AI assistance.

During the routine reporting session immediately after the index EUS examination, up to 60 days
Difference in final report completion time with versus without AI assistance
大体时间:During the assigned reporting tasks for each index EUS examination, up to 60 days

In the randomized endosonographer-reporting substudy, the within-case difference in total time to complete a final report is calculated as unassisted time minus assisted time. Total time includes review of source materials, report generation waiting time where applicable, writing, and verification. This outcome will be formally tested only if non-inferiority of the primary outcome is established.

During the assigned reporting tasks for each index EUS examination, up to 60 days
Quality of final reports in the endosonographer-reporting substudy
大体时间:Final reports from the assigned reporting tasks for each index EUS examination; assessment within 60 days after EUS.

In the randomized endosonographer-reporting substudy, the proportion of final reports accepted without significant clinical corrections will be assessed separately for reports completed with and without access to the system-generated preliminary report. Completeness and clinically important errors and omissions will also be reported.

Final reports from the assigned reporting tasks for each index EUS examination; assessment within 60 days after EUS.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月1日

初级完成 (估计的)

2028年6月30日

研究完成 (估计的)

2028年12月31日

研究注册日期

首次提交

2026年11月4日

首先提交符合 QC 标准的

2026年11月9日

首次发布 (实际的)

2026年11月10日

研究记录更新

最后更新发布 (实际的)

2026年11月10日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2026SDU-QILU-10

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅